Ventyx Biosciences, Inc. Stock Price, News & Analysis

Ventyx Biosciences (Nasdaq: VTYX) announces the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors, replacing outgoing members Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar Choksey. Both new directors bring over 30 years of experience in biotech and pharmaceuticals, enhancing the board's expertise during a critical phase of Ventyx’s development pipeline. The company focuses on oral therapies for inflammatory diseases, with multiple Phase 2 clinical trials underway, aiming to transform treatment options for conditions like psoriasis and Crohn’s disease.

Ventyx Biosciences, a clinical-stage biopharmaceutical company, will host an R&D event on January 26, 2023, in New York City from 9-11:30 a.m. ET. Key executives, including CEO Raju Mohan and CMO William Sandborn, will present insights into the company's clinical-stage and discovery programs focused on oral therapies for inflammatory diseases. The event will be available for live streaming on their website, with a replay to follow. Ventyx aims to innovate in immunology by shifting from injectable to oral medications.

Ventyx Biosciences has initiated a Phase 2 trial for VTX958, a selective TYK2 inhibitor, targeting moderate to severe plaque psoriasis. This trial, named SERENITY, follows promising Phase 1 results demonstrating strong safety and pharmacokinetic profiles. Approximately 200 patients will be enrolled to evaluate efficacy over 16 weeks, with topline data expected in Q4 2023. Ventyx plans to begin two additional Phase 2 trials for psoriatic arthritis and Crohn’s disease by the year-end, aiming to provide effective oral therapies for inflammatory diseases.

Ventyx Biosciences (Nasdaq: VTYX) will present at two upcoming investor conferences. The 5th Annual Evercore ISI HealthCONx Conference is on November 29, 2022, from 1:00-1:20 PM ET, virtually. The Piper Sandler 34th Annual Healthcare Conference is scheduled for December 1, 2022, at 9:30-9:55 AM ET in New York, NY. Management will also hold investor meetings. Webcasts of the presentations will be available on the Ventyx website, with replays accessible for 30 days.

Ventyx Biosciences is set to initiate Phase 2 trials for its allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn's disease, and psoriatic arthritis this quarter. As of September 30, 2022, the company reported cash and equivalents of $412.4 million, ensuring operational funding into 2025. The third quarter net loss was $30.5 million, up from $12.8 million year-over-year. R&D expenses rose to $25.5 million, indicating increased investment in clinical programs. A conference call will discuss these results and upcoming strategies.

Ventyx Biosciences, a clinical-stage biopharmaceutical firm, will report Q3 financial results on November 3, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and progress in its drug pipeline. Ventyx focuses on developing novel oral therapies for inflammatory diseases. Their pipeline features three clinical-stage programs targeting TYK2, S1P1R, and NLRP3, aiming to shift treatment from injectables to oral medications. The company is based in Encinitas, California.

Ventyx Biosciences, a clinical-stage biopharmaceutical company, has announced key presentations at upcoming investor conferences. Executives will discuss the company’s focus on developing innovative oral therapies for inflammatory diseases. The conferences include the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Webcasts of the presentations will be available on Ventyx's website for thirty days following each event.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced a private placement of 5,350,000 shares of common stock at $33.00 per share, aiming to raise approximately $176.6 million. The placement, led by Redmile Group, is set to close on September 20, 2022, pending customary conditions. Proceeds will fund clinical development of VTX958, VTX002, VTX2735, VTX3232, and other programs, extending the cash runway into 2025. The shares sold will not be registered under the Securities Act and a registration statement will be filed for resale. Forward-looking statements caution against relying on projections for cash and development timelines.

Ventyx Biosciences, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company focuses on developing oral therapies for inflammatory diseases. Executives will provide company insights during the 2022 Wells Fargo Healthcare Conference on September 9, 2022, at 8:00 AM ET in Boston, MA, and at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 4:40 PM ET in New York, NY. Webcasts of the presentations will be available on their website.